Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta.
A 26-year-old man with osteogenesis imperfecta and severe aortic regurgitation was scheduled for aortic valve replacement. As previously described by other authors the operation was difficult owing to the friability and weakness of the tissues. Mean blood losses of 153 mL per hour during the first 7 postoperative hours were observed. Despite normal coagulation indicators the bleeding did not stop and recombinant factor VIIa was applied at 40 microg/kg. Bleeding was successfully stopped after this single application.
Kastrup
Marc
M
Department of Anesthesiology and Intensive Care Medicine, and Cardiovascular Surgery, University Hospital Charité, Berlin, Germany.
von Heymann
Christian
C
Hotz
Holger
H
Konertz
Wolfgang F
WF
Ziemer
Sabine
S
Kox
Wolfgang J
WJ
Spies
Claudia
C
D000328:Adult; D001022:Aortic Valve Insufficiency / Q000601:surgery*; D016063:Blood Loss, Surgical / Q000503:physiopathology*; D015942:Factor VIIa / Q000008:administration & dosage*; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D008297:Male; D010013:Osteogenesis Imperfecta / Q000601:surgery*; D019106:Postoperative Hemorrhage / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage; D016896:Treatment Outcome
D011994:Recombinant Proteins; D015942:Factor VIIa